Quick Answer
Travere Therapeutics, Inc. reported Diluted EPS of $0.29 per share (loss) for fiscal year 2025.
Travere Therapeutics, Inc. Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | -$0.29 | +92.9% |
| 2024 | -$4.08 | -172.0% |
| 2023 | -$1.50 | +65.7% |
| 2022 | -$4.37 | -45.2% |
| 2021 | -$3.01 | +15.4% |
| 2020 | -$3.56 | -2.9% |
| 2019 | -$3.46 | -36.2% |
| 2018 | -$2.54 | -64.9% |
| 2017 | -$1.54 | -19.4% |
| 2016 | -$1.29 | -140.7% |
| 2015 | $3.17 | +171.6% |
| 2014 | -$4.43 | -81.6% |
| 2013 | -$2.44 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $0.28 | +140.0% | +300.0% |
| June 30, 2025 | -$0.14 | +84.6% | +70.2% |
| March 31, 2025 | -$0.47 | +73.3% | +32.9% |
| September 30, 2024 | -$0.70 | -135.5% | +23.1% |
| June 30, 2024 | -$0.91 | +19.5% | +48.3% |
| March 31, 2024 | -$1.76 | -38.6% | -189.3% |
| September 30, 2023 | $1.97 | +280.7% | +274.3% |
| June 30, 2023 | -$1.13 | -7.6% | +11.0% |
- Travere Therapeutics, Inc. showed an increase of +92.9% in Diluted EPS compared to the prior fiscal year.
- Over the 2013–2025 period, Travere Therapeutics, Inc.’s diluted eps has grown by 88.1% (from $2.44 per share (loss) to $0.29 per share (loss)).
- The most recent figure is from Travere Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 19, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: